ERBB2 and neoplasm: Because binding of the HER2 motif to T-DM1 is competitive with T-EV-bound HER2, depletion of T-EVs may increase the binding opportunities of T-DM1 to tumor cells, resulting in the enhancement of ADCC by immune cells and inhibition of HER2-mediated growth signal transduction.